12:00 AM
 | 
Jul 15, 2013
 |  BC Week In Review  |  Company News  |  Deals

Fibrocell, Intrexon deal

Fibrocell and Intrexon expanded their October 2012 deal to include treatments based on engineered autologous fibroblast cells for autoimmune and inflammatory disorders, including morphea, cutaneous eosinophilias and moderate to severe psoriasis. Intrexon will...

Read the full 145 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >